


中国药学会系列期刊/《CAJ-CD》规范执行优秀期刊/美国《化学文摘》荷兰SCOPUS等国际著名检索系统收录  
中国中文核心期刊 中国科技核心期刊 中国科学引文数据库来源期刊

CHINESE JOURNAL OF NEW DRUGS

# 中國新藥雜誌®

ISSN 1003-3734  
CN 11-2850/R  
CODEN ZXZHA6



# 9

# 2012

Vol.21 | No.9

珍稀动物药熊胆研究概况

美国FDA关于企业开展药品上市后研究和临床试验指南简介

药物代谢酶遗传多态性对药物神经毒性的影响

体内基因突变试验研究进展

吉非替尼治疗83例老年晚期非小细胞肺癌的疗效分析

1,8-二羟基-3-乙酰基-6-甲基-9,10-蒽醌的合成及对卵巢癌细胞的生长抑制活性

Z H O N G G U O X I N Y A O Z A Z H I

ISSN 1003-3734



# 目次

半月刊 1992年创刊  
第21卷第9期 2012年5月15日出版

- 945 ·世界新药之窗·  
·新药述评·
- 947 抗HIV新药利匹韦林的药理及临床评价·····何日才, 郭长彬, 周化, 等  
·新药研发论坛·
- 952 珍稀动物药熊胆研究概况·····陈艳虹, 薛红卫, 周超凡
- 956 欧盟药品上市后抽验模式分析与启示·····孙苓苓, 毕开顺
- 960 美国FDA关于企业开展药品上市后研究和临床试验指南简介·····董锋, 孙利华, 王丹  
·新药申报与审评技术·
- 964 FDA在新药注册审批中的研发激励机制研究·····杨莉, 连桂玉, 邢花, 等  
·重大新药创制专项巡礼·
- 969 HPLC-MS/MS法研究PVP包衣去甲斑蝥素壳聚糖纳米粒在大鼠体内的药代动力学·····丁信园, 王文娟, 顾宗林, 等
- 975 药物代谢酶遗传多态性对药物神经毒性的影响·····周慧, 汤纳平, 马璟
- 980 雷公藤红素对转基因小鼠原代肝细胞HBV的抑制作用·····张欣蕊, 易学瑞, 袁有成, 等
- 983 拓扑异构酶II抑制剂GL331对HepG2细胞体外生长的抑制作用·····王娅杰, 陈晓光, 肖志艳, 等  
·生物医药前沿·
- 989 非人灵长类模型在生殖发育毒性评价中的应用·····袁芳, 潘晓靓, 林海霞, 等  
·综述·
- 994 体内基因突变试验研究进展·····张铭, 周长慧, 王庆利, 等
- 998 丙泊酚对缺血再灌注损伤期间多脏器功能保护的研究进展·····谢兰云, 雷志礼, 宁新宇  
·临床研究·
- 1002 吉非替尼治疗83例老年晚期非小细胞肺癌的疗效分析·····刘雨桃, 郝学志, 李峻岭, 等
- 1007 新辅助化疗方案治疗局部晚期乳腺癌60例的疗效分析·····刘大海, 卢振锋
- 1010 右美托咪定对颅内动脉瘤夹闭手术苏醒期不良反应的作用·····顾旭华, 王翠玉
- 1013 复方苦参注射液联合顺铂胸腔内注射治疗恶性血液病并发胸腔积液24例·····庄海峰, 任金贤, 周郁鸿, 等
- 1016 盐酸特比萘芬片在健康人体中的相对生物利用度及生物等效性试验·····陈红, 孙艳伏, 蔡丽伟, 等
- 1020 七氟烷与瑞芬太尼在抑制强直电刺激中的药理学相互作用·····王慧玲, 杨璐, 张利萍, 等  
·实验研究·
- 1026 作用于秋水仙碱结合位点的微管蛋白抑制剂药效团的构建·····刘钢, 刘宗英, 孟帅, 等
- 1032 延胡索合剂对小鼠吡柔比星外渗性损伤的防治及机制·····孙甜甜, 王华庆, 钱正子, 等
- 1036 1,8-二羟基-3-乙酰基-6-甲基-9,10蒽醌的合成及对卵巢癌细胞的生长抑制·····梁燕, 侯华新, 黎丹戎, 等
- 1042 c-Met小分子抑制剂XL880的合成·····严家菊, 刘靖, 王林, 等
- 1046 普兰林肽的固相合成·····韩月, 尹志峰, 赵红玲, 等
- 1050 三七总皂苷口服制剂的处方前研究·····赖玲, 刘华钢, 文丽, 等
- 1054 生脉饮治疗慢性心衰大鼠不同提取工艺的比较·····姜淋洁, 成志煌, 胡雪峰, 等
- 1059 五味子乙素对实验性矽肺大鼠肺组织MMP-2和TIMP-1蛋白含量的影响·····郭民, 樊林花, 刘田福  
·不良反应·
- 1063 国内期刊药源性肺疾病文献的回顾性分析·····刘文生, 温晓娜

[期刊基本参数] CN11-2850/R\*1992\*sm\*A4\*122\*zh\*P\*¥30.00\*\*27\*2012-09

责任编辑 韩培 英文审校 魏尔清 杜小莉

# CONTENTS

CHINESE JOURNAL OF NEW DRUGS

- 947 Pharmacological and clinical evaluation of a new anti-HIV drug, rilpivirine
- 952 Research of rare animal medicine bear gall
- 956 A look into the EU post-marketing sampling and testing model and its inspiration to China
- 960 FDA Guidance for Industry Postmarketing Studies and Clinical Trials in US
- 964 Research on the R&D incentives of FDA in the new drug registration and approval
- 969 Study on pharmacokinetic profile of PVP-coated norcantharidin-chitosan nanoparticles in rats by HPLC-MS/MS
- 975 Effects of metabolizing enzyme polymorphisms on drug related neurotoxicity
- 980 Inhibitory effects of celastrol on primary hepatocytes of HBV transgenic mice
- 983 GL331, a topoisomerase II inhibitor, induces growth arrest in HepG2 cells *in vitro*
- 989 Nonhuman primates as animal models for developmental and reproductive toxicity study
- 994 Progress in the development of *in vivo* gene mutation assays
- 998 Protection of propofol on viscera function during ischemia reperfusion
- 1002 Efficacy analysis for 83 elderly patients with advanced non-small cell lung cancer treated with gefitinib
- 1007 Efficacy analysis of treatment of locally advanced breast cancer with neoadjuvant chemotherapy
- 1010 Effects of dexmedetomidine on responses during the recovery from general anesthesia in clipping of intracranial aneurysm
- 1013 Matrine injection combined with intrapleural cisplatin in treatment of 24 patients with hematologic malignancies complicated by pleural effusion
- 1016 Relative bioavailability and bioequivalence study of terbinafine hydrochloride tablets in healthy volunteers
- 1020 Pharmacodynamic interaction between sevoflurane and remifentanyl regarding tolerance of responses to electrical tetanus stimuli
- 1026 Development and validation of pharmacophore model of tubulin inhibitors which bind to the colchicine-site
- 1032 Effect and mechanism of *Corydalis ambigua* mixture on pirarubicin-induced extravasation injury in mice
- 1038 Synthesis of 1,8-dihydroxy-3-acetyl-6-methyl-9,10-anthraquinone and its inhibition effect on ovarian carcinoma cells SKOV3
- 1042 Synthesis of a small molecular inhibitor of c-Met, XL880
- 1046 Solid phase synthesis of pramlintide
- 1050 Pre-formulation study on panax notoginseng saponins oral formulation
- 1054 Comparison of the effects of Shengmai Yin prepared by different extraction methods on rats with chronic heart failure
- 1059 Effect of schisandrin B on the content of MMP-2 and TIMP-1 protein in lungs of rats with silica-induced silicosis
- 1063 Retrospective analysis of drug-induced pulmonary diseases reported in domestic literatures
- HE Ri-cai, GUO Chang-bin, ZHOU Hua, *et al*  
CHEN Yan-hong, XUE Hong-wei, ZHOU Chao-fan
- SUN Ling-ling, BI Kai-shun  
DONG Duo, SUN Li-hua, WANG Dan  
YANG Li, LIAN Gui-yu, XING Hua, *et al*
- DING Xin-yuan, WANG Wen-juan, GU Zong-lin, *et al*  
ZHOU Hui, TANG Na-ping, MA Jing  
ZHANG Xin-rui, YI Xue-rui, YUAN You-cheng, *et al*  
WANG Ya-jie, CHEN Xiao-guang, XIAO Zhi-yan, *et al*
- YUAN Fang, PAN Xiao-liang, LIN Hai-xia, *et al*  
ZHANG Ming, ZHOU Chang-hui, WANG Qing-li, *et al*  
XIE Lan-yun, LEI Zhi-li, NING Xin-yu
- LIU Yu-tao, HAO Xue-zhi, LI Jun-ling, *et al*  
LIU Da-hai, LU Zhen-duo
- GU Xu-hua, WANG Cui-yu
- ZHUANG Hai-feng, REN Jin-xian, ZHOU Yu-hong, *et al*  
CHEN Hong, SUN Yan-fu, CAI Li-wei, *et al*  
WANG Hui-ling, YANG Lu, ZHANG Li-ping, *et al*
- LIU Ling, LIU Zong-ying, MENG Shuai, *et al*  
SUN Tian-tian, WANG Hua-qing, QIAN Zheng-zi, *et al*
- LIANG Yan, HOU Hua-xin, LI Dan-rong, *et al*  
YAN Jia-ju, LIU Jing, WANG Lin, *et al*  
HAN Yue, YIN Zhi-feng, ZHAO Hong-ling, *et al*  
LAI Ling, LIU Hua-gang, WEN Li, *et al*
- JIANG Lin-jie, CHENG Zhong-huang, HU Xue-feng, *et al*  
GUO Min, FAN Lin-hua, LIU Tian-fu
- LIU Wen-sheng, WEN Xiao-na

Directed by: State Food and Drug Administration  
Sponsored by: China Medical Science Press  
China National Pharmaceutical Group Corp.  
Chinese Pharmaceutical Association

Editor-in-Chief: SANG Guo-wei

Board Chairman: SHI Sheng-yi

Director: SHI Sheng-yi SONG Rui-lin WU Shao-zhen LI Shao-li  
DENG Jin-dong ZHU Jing-jin FENG Lan

Board of Directors Secretary: ZHOU Ying

General Manager: FENG Lan

Deputy General Manager: LIU Da-wei

Deputy Editorial Department Director: YANG Qing

Chief Marketing Officer: HAO De-zhi

Editor and Publisher: Chinese Journal of New Drugs Co., Ltd.

Address: Floor 8, Luyang Building, No.6 Beisanhuanzhonglu  
Xicheng District, Beijing 100120, China

Tel: (010)82282302 / 82282300 / 82282301 / 82282329 / 82282309 / 82282326

Fax: (010)82282289

Website: <http://www.newdrug.cn>

E-mail: [cnj2009@gmail.com](mailto:cnj2009@gmail.com)

Printer: Beijing Jinqubao Printing Co., Ltd.

Domestic Distribution: Beijing Post Offices

Overseas Distribution: China International Book Trading Corp.  
(P.O.Box 399 Beijing, China)

Domestic Subscription: Local Post Offices

Periodical Registration: ISSN 1003-3734 CN 11-2850/R

Publication Date: May 15, 2012

Copyright: 2012 by Chinese Journal of New Drugs Co., Ltd.